切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2018, Vol. 07 ›› Issue (06) : 277 -279. doi: 10.3877/cma.j.issn.2095-3216.2018.06.008

所属专题: 文献

综述

肾病综合征儿童矮身材的机制与治疗
卢枚1, 高春林1, 杨晓1, 夏正坤1,()   
  1. 1. 210002 南京,南方医科大学临床医学院(南京军区南京总医院)儿科
  • 收稿日期:2018-03-05 出版日期:2018-12-28
  • 通信作者: 夏正坤

Mechanism and treatment of short stature in children with nephrotic syndrome

Mei Lu1, Chunlin Gao1, Xiao Yang1, Zhengkun Xia1,()   

  1. 1. Department of Pediatrics, Nanjing General Hospital of Nanjing Military Region, Clinical Medical College of Southern Medical University, Nanjing 210002, China
  • Received:2018-03-05 Published:2018-12-28
  • Corresponding author: Zhengkun Xia
  • About author:
    Corresponding author: Xia Zhengkun, Email:
引用本文:

卢枚, 高春林, 杨晓, 夏正坤. 肾病综合征儿童矮身材的机制与治疗[J/OL]. 中华肾病研究电子杂志, 2018, 07(06): 277-279.

Mei Lu, Chunlin Gao, Xiao Yang, Zhengkun Xia. Mechanism and treatment of short stature in children with nephrotic syndrome[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(06): 277-279.

原发性肾病综合征(PNS)是儿童常见肾脏病。糖皮质激素及其他免疫抑制剂的广泛应用使肾病综合征的治愈率及生存率得到了显著的提高。但肾病综合征自身复杂的病理生理机制及糖皮质激素等免疫抑制剂的长期使用导致了肾病综合征患儿生长发育迟缓问题越显突出,而儿童时期生长发育对成年后的身高具有重要影响。对于PNS儿童矮身材的防治目前尚无系统的成熟的方案,应用重组人生长激素治疗矮身材儿童是目前的主要手段,但其安全性及有效性仍需要进一步的研究给予证实。

Primary nephrotic syndrome (PNS) is a common kidney disease in children. The widespread use of glucocorticoids and other immunosuppressive agents has significantly improved the cure rate and survival rate of nephrotic syndrome patients. However, the complex pathophysiological mechanism of nephrotic syndrome and the long-term use of immunosuppressive agents such as glucocorticoids have led to the more prominent growth retardation in children with nephrotic syndrome, although the growth and development in childhood has an important influence on their heights at adult. There is no systematic and mature scheme for the prevention and treatment of short stature in children with PNS. The use of recombinant human growth hormone to treat short stature of children with PNS is currently the main means, but its safety and efficacy still need further researches for confirmation.

[12]
Ocaranza P, Lammoglia JJ, Iniguez G, et al. Effects of thyroid hormone on the GH signal transduction pathway [J]. Growth Horm IGF Res, 2014, 24(1): 42-46.
[13]
Rogol AD. Sex steroids, growth hormone, leptin and the pubertal growth spurt [J]. Endocr Dev, 2010, 17: 77-85.
[14]
de Lemos SG, Tirapegui J. Growth hormone secretion and nutrition [J]. Arq Gastroenterol, 1994, 31(4): 159-172.
[15]
易著文,刘建华. 原发性肾病综合征患儿生长激素-胰岛素样生长因子轴的变化与生长障碍[J].中华儿科杂志,1999,37(4):235.
[16]
Allen DB. Inhaled corticosteroids and growth: still an issue after all these years [J]. J Pediatr, 2015, 166(2): 463-469.
[17]
Altowati MA, Russell RK, Ahmed SF. Endocrine therapy for growth retardation in paediatric inflammatory bowel disease [J]. Paediatr Drugs, 2014, 16(1): 29-42.
[18]
Wolthers OD, Ramshanker N, Heuck C, et al. The timing of administration of exogenous glucocorticoid affects 24hour growth hormone secretion in children [J]. Growth Horm IGF Res, 2017, 35(1): 40-44.
[19]
Tsampalieros A, Gupta P, Denburg MR, et al. Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome [J]. J Bone Miner Res, 2013, 28(3): 480-488.
[20]
Ribeiro D, Zawadynski S, Pittet LF, et al. Effect of glucocorticoids on growth and bone mineral density in children with nephrotic syndrome [J]. Eur J Pediatr, 2015, 174(7): 911-917.
[21]
Hartmann K, Koenen M, Schauer S, et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy [J]. Physiol Rev, 2016, 96(2): 409-447.
[22]
Simmonds J, Grundy N, Trompeter R, et al. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome [J]. Arch Dis Child, 2010, 95(2): 146-149.
[23]
Skrzypczyk P, Panczyk-Tomaszewska M, Roszkowska-Blaim M, et al. Long-term outcomes in idiopathic nephrotic syndrome: from childhood to adulthood [J]. Clin Nephrol, 2014, 81(3): 166-173.
[24]
Marimuthu V, Krishnamurthy S, Rajappa M. Non-autoimmune subclinical and overt hypothyroidism in idiopathic steroid-resistant nephrotic syndrome in children [J]. Indian Pediatr, 2017, 54(11): 925-929.
[25]
Mehlman CT, Ain MC. Evaluation of the child with short stature [J]. Orthop Clin North Am, 2015, 46(4): 523-531.
[26]
Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults [J]. Eur J Endocrinol, 2016, 174(2): P1-P9.
[1]
中华医学会儿科学分会肾脏学组.儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)[J].中华儿科杂志,2017,(10):729-734.
[2]
中华医学会儿科学分会肾脏学组.激素耐药型肾病综合征诊治循证指南(2016)[J].中华儿科杂志,2017,(11):805-809.
[3]
Hjorten R, Anwar Z, Reidy KJ. Long-term outcomes of childhood onset nephrotic syndrome [J]. Front Pediatr, 2016, 4: 53.
[4]
Donatti TL, Koch VH. Final height of adults with childhood-onset steroid-responsive idiopathic nephrotic syndrome [J]. Pediatr Nephrol, 2009, 24(12): 2401-2408.
[5]
闫洁.儿童矮身材诊治进展[J].中华实用儿科临床杂志,2016,(23):1778-1782.
[6]
Saenger PH, Mejia-Corletto J. Long-acting growth hormone: an update [J]. Endocr Dev, 2016, 30: 79-97.
[7]
Kanaley JA. Growth hormone, arginine and exercise [J]. Curr Opin Clin Nutr Metab Care, 2008, 11(1): 50-54.
[8]
Tritos NA, Biller BM. Growth hormone and bone [J]. Curr Opin Endocrinol Diabetes Obes, 2009, 16(6): 415-422.
[9]
Rosen CJ. Growth hormone and aging [J]. Endocrine, 2000, 12(2): 197-201.
[10]
Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age [J]. Best Pract Res Clin Endocrinol Metab, 2016, 30(6): 737-747.
[11]
Pascual A, Aranda A. Thyroid hormone receptors, cell growth and differentiation [J]. Biochim Biophys Acta, 2013, 1830(7): 3908-3916.
[27]
Loke KY, Yap HK, Zhou X, et al. Efficacy and safety of one year of growth hormone therapy in steroid-dependent nephrotic syndrome [J]. J Pediatr, 1997, 130(5): 793-799.
[28]
Sato M, Ito S, Ogura M, et al. Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome [J]. Pediatr Nephrol, 2014, 29(8): 1373-1379.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 曹琮沅, 黄烁金, 何倩婷, 王安训. 平阳霉素复合剂治疗口腔颌面部脉管畸形的有效性和安全性[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 368-374.
[3] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[4] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[5] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[6] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[7] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[8] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[9] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[10] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[11] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[12] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[13] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?